Evidence for the recognition of non‐nucleotide antagonists within the transmembrane domains of the human P2Y1 receptor

Publisher Website
Google Scholar
Abstract
Site‐directed mutagenesis was used to search for amino acid residues of the human P2Y1 receptor involved in the binding of the P2 receptor antagonists pyridoxal‐5′‐phosphate‐6‐azophenyl‐2,4‐disulfonate (PPADS), its analogue 6‐(2′‐chloro‐phenylazo)‐pyridoxal‐α5‐phosphate (MRS 2210), the suramin analogue 8‐8′‐[carbonylbis(imino‐3,1‐phenylene)]bis(1,3,5‐naphthalene‐trisulfonate) (NF023), and Reactive blue 2. Receptors containing single amino acid replacements at positions in transmembrane helical domains (TMs) 3, 5, 6, and 7 critical for the activation of the receptor by nucleotide agonists were expressed in COS‐7 (African green monkey kidney) cells. Inositol phosphate accumulation was induced by 2‐methylthioadenosine 5′‐diphosphate (2‐MeSADP). In wild type human P2Y1 receptors, PPADS (10 to 60 µM), MRS 2210 (10 µM), NF023 (100 µM), and Reactive blue 2 (10 µM) shifted the concentration‐response curve of 2‐MeSADP in a parallel manner to the right. For PPADS, a pA2 value of 5.2 was estimated. The shifts caused by MRS 2210, NF023, and Reactive blue 2 corresponded to apparent pKB values of 5.6, 5.0, and 5.8, respectively. In K280A mutant receptors, the affinities of PPADS, MRS 2210, NF023, and Reactive blue 2 were about 6‐ to 60‐fold lower than those observed at wild type receptors. The K280A mutation also caused an approximately 1,000‐fold increase in the EC50 value of the agonist 2‐MeSADP, similar to previous observations. In contrast, no major change in antagonistic potency was observed at receptors with other mutations in TMs 3, 5, 6, and 7. Thus, the residue Lys280 (6.55), which is located within the upper third of TM 6 of the human P2Y1 receptor, is not only critical for the activation of the receptor but also plays an important role in the binding of pyridoxal derivatives and a number of other chemically unrelated P2 receptor antagonists. Lys280 seems to belong to an overlapping region of the respective binding sites. Drug Dev. Res. 57:173–181, 2002. Published 2003 Wiley‐Liss, Inc.
Funding Information
  • Deutsche Forschungsgemeinschaft

This publication has 23 references indexed in Scilit: